Study of Senl-T7 CAR T Cell Therapy for Relapsed or Refractory CD7 Acute T-Cell Lymphoblastic Leukemia and Lymphoma

What this Trial Is About

Researchers are evaluating Senl-T7 CAR T cells in patients with relapsed or refractory CD7 acute T lymphoblastic leukemia or T lymphoblastic lymphoma. This open, prospective, dose-escalation clinical study aims to assess the safety and effectiveness of Senl-T7 while collecting pharmacokinetic and pharmacodynamic data to better understand its behavior in the body. Participants will receive preconditioning treatment before being infused with the Senl-T7 CAR T cells, which include components targeting CD7 on cancer cells. After infusion, patients will be closely monitored for adverse reactions and treatment response to evaluate safety and remission rates. During the study, patients will undergo regular evaluations, including monitoring for side effects within the first month and assessing remission status at three months post-infusion. Researchers will track adverse events and treatment outcomes to determine the impact of Senl-T7 on the disease. Participation duration can extend up to several months as outcomes are measured over time.

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL